| Medical and Health Sciences | Lifetime | 407 | NL 8 | 99.98 |
| Oncology | Lifetime | 42 | NL 2 | 99.93 |
| Pharmacology | Lifetime | 58 | NL 2 | 99.45 |
| Infectious Diseases | Lifetime | 416 | NL 17 | 98.50 |
| Pulmonary and Respiratory Medicine | Lifetime | 909 | NL 24 | 98.52 |
| Pathology and Forensic Medicine | Lifetime | 431 | NL 8 | 98.23 |
| Pediatrics, Perinatology and Child Health | Lifetime | 568 | NL 18 | 98.27 |
| Spectroscopy and Chemical Instrumentation | Lifetime | 559 | NL 11 | 96.73 |
| Medical Genetics | Lifetime | 519 | NL 11 | 95.05 |
| Hematology | Lifetime | 651 | NL 23 | 94.72 |
| Occupational Therapy | Lifetime | 352 | NL 7 | 93.04 |
| Toxicology | Lifetime | 204 | NL 10 | 90.14 |
| Pharmaceutical Science | Lifetime | 639 | NL 6 | 85.53 |
| Virology | Lifetime | 480 | NL 7 | 84.80 |
| Oncology | 2021-2025 | 323 | NL 8 | 96.83 |
| Pharmacology | 2021-2025 | 95 | NL 5 | 88.42 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 873 | NL 31 | 88.37 |
| Cancer therapeutics and mechanisms | Lifetime | 2 | NL 1 | 99.88 |
| Drug Transport and Resistance Mechanisms | Lifetime | 7 | NL 1 | 99.88 |
| Cancer Treatment and Pharmacology | Lifetime | 16 | NL 1 | 99.92 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 1 | NL 1 | 99.85 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 17 | NL 1 | 99.71 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 18 | NL 1 | 99.79 |
| HIV/AIDS drug development and treatment | Lifetime | 47 | NL 1 | 99.69 |
| Colorectal Cancer Treatments and Studies | Lifetime | 50 | NL 4 | 99.74 |
| Neutropenia and Cancer Infections | Lifetime | 42 | NL 2 | 99.46 |
| Safe Handling of Antineoplastic Drugs | Lifetime | 6 | NL 2 | 98.39 |
| Lung Cancer Treatments and Mutations | Lifetime | 281 | NL 12 | 99.27 |
| Biosimilars and Bioanalytical Methods | Lifetime | 50 | NL 8 | 98.56 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 44 | NL 6 | 98.69 |
| Lung Cancer Research Studies | Lifetime | 201 | NL 11 | 99.14 |
| Chemotherapy-related skin toxicity | Lifetime | 27 | NL 2 | 98.49 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 296 | NL 6 | 99.11 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 175 | NL 3 | 99.05 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 128 | NL 4 | 98.76 |
| HER2/EGFR in Cancer Research | Lifetime | 215 | NL 6 | 99.03 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 282 | NL 8 | 98.50 |
| Neuroendocrine Tumor Research Advances | Lifetime | 374 | NL 15 | 98.61 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 363 | NL 15 | 97.88 |
| HIV Research and Treatment | Lifetime | 566 | NL 13 | 98.57 |
| Biochemical and Molecular Research | Lifetime | 355 | NL 6 | 97.47 |
| PARP inhibition in cancer therapy | Lifetime | 195 | NL 3 | 97.29 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 264 | NL 3 | 97.02 |
| Mass Spectrometry Techniques and Applications | Lifetime | 841 | NL 20 | 97.43 |
| Pharmaceutical studies and practices | Lifetime | 461 | NL 32 | 96.74 |
| Acute Lymphoblastic Leukemia research | Lifetime | 718 | NL 27 | 97.51 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 603 | NL 13 | 97.10 |
| Chemical Reactions and Isotopes | Lifetime | 429 | NL 4 | 95.63 |
| Multiple Myeloma Research and Treatments | Lifetime | 818 | NL 14 | 96.16 |
| Advanced Proteomics Techniques and Applications | Lifetime | 512 | NL 15 | 95.32 |
| Protein purification and stability | Lifetime | 616 | NL 17 | 94.97 |
| Melanoma and MAPK Pathways | Lifetime | 491 | NL 13 | 95.28 |
| Advanced Breast Cancer Therapies | Lifetime | 591 | NL 11 | 95.38 |
| HIV-related health complications and treatments | Lifetime | 795 | NL 13 | 94.61 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 800 | NL 47 | 91.89 |
| Synthesis of Indole Derivatives | Lifetime | 356 | NL 3 | 89.89 |
| Natural Product Synthesis and Anticancer Bioactivity | Lifetime | 625 | NL 8 | 87.73 |
| Silymarin and Mushroom Poisoning | Lifetime | 506 | NL 1 | 71.43 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 164 | NL 6 | 91.58 |
| Cancer Treatment and Pharmacology | 2021-2025 | 394 | NL 10 | 92.05 |
| Pharmacogenetics and Drug Metabolism | 2021-2025 | 139 | NL 6 | 91.08 |
| HIV/AIDS drug development and treatment | 2021-2025 | 387 | NL 10 | 90.07 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 769 | NL 33 | 91.05 |
| Cancer therapeutics and mechanisms | 2021-2025 | 329 | NL 3 | 84.91 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 364 | NL 20 | 85.63 |
| Neutropenia and Cancer Infections | 2021-2025 | 513 | NL 15 | 76.68 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 856 | NL 32 | 78.70 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 948 | NL 17 | 59.87 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 490 | NL 5 | 56.47 |
| Safe Handling of Antineoplastic Drugs | 2021-2025 | 225 | NL 12 | 44.10 |
